Sort
21,281 grants matching “influenza”
Templated Chemistry for RNA Analysis
$299,879Eric T. Kool · Stanford University · R01 · FY2013 · GM
Discovery of Critical Host Genes Enabling Resistance to HIV-1 Infection as Therap
$299,878Hanwen Mao · Functional Genetics, Inc. · R43 · FY2008 · AI
Joint Initiative in Vaccine Economics 5
$299,848David W Hutton · University Of Michigan At Ann Arbor · U01 · FY2017 · IP
Analogs of GTP as novel inhibitors of bacterial c-di-GMP-synthesizing enzymes
$299,848George E Wright · Glsynthesis, Inc. · R43 · FY2010 · AI
CORRELATIONS--STRUCTURE DYNAMICS FUNCTIONS IN CHANNELS
$299,838Florida State University · R01 · FY2004 · AI
Monitoring System For Vector-Based Influenza Vaccine
$299,837Matthew M. Ferris · Indevr, Inc. · R43 · FY2006 · AI
Race and Ethnicity in Vaccination for Influenza in Vulnerable Elderly (REVIVE)
$299,826Nancy Jean Kupka · Joint Commission · U01 · FY2011 · IP
PA-22-176, SBIR, Phase I, Novel Bispecific Nanotherapeutics as Broad-Spectrum Influenza Antivirals Refractory to Viral Escape
$299,794Crystal Lee Moyer · Eitr Biologics, Inc. · R43 · FY2023 · IP
Rapid, Multiplexed Point-Of-Care Molecular Detection of Respiratory Pathogens without Sample Prep
$299,766Hyundae Cho · Crosslife Technologies, Inc. · R44 · FY2019 · AI
Class II Processing Delineated by Flu Glycoproteins
$299,750Thomas Jefferson University · R01 · FY2004 · AI
HUMAN PROTEOLYTIC FOR IgA NEPHROPATHY
$299,749Robert F Balint · Cytodesign, Inc. · R43 · FY2013 · AI
An RSV Prefusion F Vaccine that Overcomes Immunosenescence
$299,740Mark Yondola · Calder Biosciences, Inc. · R44 · FY2019 · AG
mTOR Regulation of Basal Antiviral Immunity in the Elderly
$299,736Joan B Mannick · Restorbio, Inc. · R01 · FY2019 · AG
Mechanism for activation of the antiviral kinase PKR
$299,724James L Cole · University Of Connecticut Storrs · R01 · FY2009 · AI
Construct novel influenza A (H1N1) virus chimeric HA genes for development of bro
$299,710Ying Fang · South Dakota State University · R15 · FY2010 · AI
FAIRS AND EXHIBITIONS CAN SPREAD INFLUENZA A VIRUSES (IAV) BETWEEN ANIMALS AND PEOPLE, CAUSING ILLNESSES THAT RANGE FROM MILD TO SEVERE. ANIMALS AND PEOPLE FROM DIFFERENT PLACES ARE IN CLOSE CONTACT FOR DAYS, WHICH GOES AGAINST STANDARD BIOSECURITY PRACTICES. WE WANT TO REDUCE THE RISK OF H5 INFLUENZA AND OTHER DISEASES AT ANIMAL FAIRS BY TEACHING BIOSECURITY TO YOUTH AND FAIR MANAGERS. TO DO THIS, WE WILL CREATE REQUIRED LEARNING MODULES FOR 4-H YOUTH ON BIOSECURITY AND ANIMAL-TO-HUMAN DISEASE RISKS. WE WILL ALSO HELP FAIR LEADERS LEARN ABOUT BIOSECURITY AND MAKE A PLAN FOR THEIR EVENT. OUR 4-H CURRICULUM WILL COVER MORE THAN BASIC BIOSECURITY. DECISION-MAKERS WILL LEARN TO REVIEW CURRENT PRACTICES, REDUCE RISKS, CHECK IMPROVEMENTS, AND IMPROVE LONG-TERM BIOSECURITY. YOUTH WILL LEARN IMPORTANT SKILLS TO STAY INFORMED, WHILE FAIR BOARDS WILL BE READY TO SPOT RISKS AND SOLVE PROBLEMS FOR BOTH CURRENT AND FUTURE EVENTS. THIS APPROACH WILL MAKE FAIRS SAFER FOR BOTH PEOPLE AND ANIMALS.
$299,708Regents Of The University Of Minnesota · · FY2025 · National Institute of Food and Agriculture
Surveillance and Response to Avian and Pandemic Influenza by the National
$299,703Ilesh Jani · Instituto Nacional De Saude · U51 · FY2013 · IP
MVA-based vaccines against highly pathogenic avian influenza
$299,702Dan Thomas Stinchcomb · Inviragen, Inc. · R41 · FY2007 · AI
Microfluidic Viral Infection Assay
$299,699John Yin · Bellbrook Labs, Llc · R41 · FY2008 · AI
Improved Influenza Vaccine Efficacy Through Infection Mimicry
$299,698Kathryn Kosuda · Vaxess Technologies, Inc. · R44 · FY2019 · AI
Pattern Recognition Molecule Mindin As Adjuvant
$299,648Duke University · U01 · FY2005 · AI
Joint Initiative in Vaccine Economics 5
$299,594David W Hutton · University Of Michigan At Ann Arbor · U01 · FY2016 · IP
Simulation of Proton Translocation in Biomolecules
$299,584Gregory A. Voth · University Of Chicago · R01 · FY2013 · GM
Synthetic Nanoparticle based Universal Influenza Vaccine
$299,513Ramila Philip · Immunotope, Inc. · R43 · FY2010 · AI
Race and Ethnicity in Vaccination for Influenza in Vulnerable Elderly (REVIVE)
$299,472Nancy Jean Kupka · Joint Commission · U01 · FY2010 · IP